CN114222752B - 抗组织因子抗体-药物缀合物及相关方法 - Google Patents

抗组织因子抗体-药物缀合物及相关方法

Info

Publication number
CN114222752B
CN114222752B CN202080054283.1A CN202080054283A CN114222752B CN 114222752 B CN114222752 B CN 114222752B CN 202080054283 A CN202080054283 A CN 202080054283A CN 114222752 B CN114222752 B CN 114222752B
Authority
CN
China
Prior art keywords
antibody
seq
amino acid
acid sequence
cdr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080054283.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN114222752A (zh
Inventor
J-W·托伊尼森
A·G·蔡
T-S·米根
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enzymatic British Columbia Ltd
Exelixis Inc
Original Assignee
Enzymatic British Columbia Ltd
Zymeworks BC Inc
Iconock Treatment Co
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=74100836&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN114222752(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Enzymatic British Columbia Ltd, Zymeworks BC Inc, Iconock Treatment Co, Exelixis Inc filed Critical Enzymatic British Columbia Ltd
Publication of CN114222752A publication Critical patent/CN114222752A/zh
Application granted granted Critical
Publication of CN114222752B publication Critical patent/CN114222752B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080054283.1A 2019-07-03 2020-07-02 抗组织因子抗体-药物缀合物及相关方法 Active CN114222752B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962870644P 2019-07-03 2019-07-03
US62/870,644 2019-07-03
PCT/US2020/040711 WO2021003399A1 (en) 2019-07-03 2020-07-02 Anti-tissue factor antibody-drug conjugates and related methods

Publications (2)

Publication Number Publication Date
CN114222752A CN114222752A (zh) 2022-03-22
CN114222752B true CN114222752B (zh) 2025-11-14

Family

ID=74100836

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080054283.1A Active CN114222752B (zh) 2019-07-03 2020-07-02 抗组织因子抗体-药物缀合物及相关方法

Country Status (21)

Country Link
US (1) US20220257789A1 (https=)
EP (1) EP3994150A4 (https=)
JP (1) JP7709636B2 (https=)
KR (1) KR20220029724A (https=)
CN (1) CN114222752B (https=)
AR (1) AR119346A1 (https=)
AU (1) AU2020299398C9 (https=)
BR (1) BR112021025720A2 (https=)
CA (1) CA3141428A1 (https=)
CL (2) CL2021003414A1 (https=)
CO (1) CO2022001083A2 (https=)
CR (1) CR20220047A (https=)
DO (1) DOP2021000268A (https=)
EA (1) EA202193309A1 (https=)
EC (1) ECSP22007981A (https=)
IL (1) IL289138A (https=)
MX (1) MX2021015974A (https=)
PE (1) PE20221004A1 (https=)
PH (1) PH12021553289A1 (https=)
TW (1) TWI879780B (https=)
WO (1) WO2021003399A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020007077A (es) 2018-01-04 2020-10-28 Iconic Therapeutics Inc Anticuerpos anti-factor tisular, conjugados anticuerpo-farmaco y metodos relacionados.
TW202342517A (zh) * 2022-01-12 2023-11-01 美商艾康尼醫療有限責任公司 使用抗組織因子抗體之炎性疾病治療
JP2025508779A (ja) * 2022-02-24 2025-04-10 エボポイント、バイオサイエンシズ、カンパニー、リミテッド 抗体及びその薬物コンジュゲート並びに用途
WO2023172951A1 (en) * 2022-03-09 2023-09-14 Exelixis, Inc. Methods of treating solid tumors with anti-tissue factor antibody-drug conjugates
US20250276077A1 (en) * 2022-04-05 2025-09-04 Immunome, Inc. Epha2 antibodies
CN116143929B (zh) * 2023-02-03 2023-08-01 北京基科晟斯医药科技有限公司 抗重组人凝血因子VIIa-Fc融合蛋白的抗体及其应用
CN116789837B (zh) * 2023-03-24 2024-02-23 山西纳安生物科技股份有限公司 一种抗组织因子人源化抗体及制备的抗体偶联药物和应用
CN118772282A (zh) * 2023-04-10 2024-10-15 复旦大学 靶向组织因子的纳米抗体及偶联物的制备方法和用途
CN121039165A (zh) * 2023-04-28 2025-11-28 江苏恒瑞医药股份有限公司 抗tf抗体和抗tf抗体-药物偶联物及其医药用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019136309A1 (en) * 2018-01-04 2019-07-11 Iconic Therapeutics, Inc. Anti-tissue factor antibodies, antibody-drug conjugates, and related methods
CN112203695A (zh) * 2018-03-21 2021-01-08 展马博联合股份有限公司 用基于铂的试剂和抗组织因子抗体-药物偶联物的组合治疗癌症的方法
CN116322787A (zh) * 2020-06-29 2023-06-23 展马博联合股份有限公司 抗组织因子抗体-药物偶联物及其在癌症治疗中的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012031727B1 (pt) * 2010-06-15 2022-03-29 Genmab A/S Conjugado de droga-anticorpo, composição farmacêutica, e, uso do conjugado de droga- anticorpo
ES2905569T3 (es) * 2014-09-17 2022-04-11 Zymeworks Inc Compuestos citotóxicos y antimitóticos y métodos para utilizarlos
SI3280441T1 (sl) * 2015-04-07 2022-01-31 Alector Llc Protitelesa anti-sortilin in metoda njihove uporabe
US11306144B2 (en) * 2017-08-25 2022-04-19 Five Prime Therapeutics, Inc. B7-H4 antibodies and methods of use thereof
EA202090741A1 (ru) 2017-11-02 2020-07-30 Генмаб А/С Конъюгаты антитела к тканевому фактору и лекарственного средства и их применение в лечении рака
CN111727075B (zh) * 2017-11-27 2024-04-05 普渡制药公司 靶向人组织因子的人源化抗体

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019136309A1 (en) * 2018-01-04 2019-07-11 Iconic Therapeutics, Inc. Anti-tissue factor antibodies, antibody-drug conjugates, and related methods
CN111818943A (zh) * 2018-01-04 2020-10-23 伊科尼克治疗公司 抗组织因子抗体、抗体-药物缀合物及相关方法
CN112203695A (zh) * 2018-03-21 2021-01-08 展马博联合股份有限公司 用基于铂的试剂和抗组织因子抗体-药物偶联物的组合治疗癌症的方法
CN116322787A (zh) * 2020-06-29 2023-06-23 展马博联合股份有限公司 抗组织因子抗体-药物偶联物及其在癌症治疗中的用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
人源化抗组织因子(TF)抗体的制备及杀伤结肠癌细胞和抑制细胞迁移的机制;赵亚蕊 等;细胞与分子免疫学杂志;20210218;第37卷(第02期);168-173 *

Also Published As

Publication number Publication date
CL2024003094A1 (es) 2025-02-07
AU2020299398C9 (en) 2026-01-22
TW202116357A (zh) 2021-05-01
US20220257789A1 (en) 2022-08-18
TWI879780B (zh) 2025-04-11
CL2021003414A1 (es) 2022-09-09
JP7709636B2 (ja) 2025-07-17
CO2022001083A2 (es) 2022-05-20
IL289138A (en) 2022-02-01
CA3141428A1 (en) 2021-01-07
KR20220029724A (ko) 2022-03-08
AU2020299398C1 (en) 2025-10-02
WO2021003399A1 (en) 2021-01-07
EP3994150A1 (en) 2022-05-11
EA202193309A1 (ru) 2022-03-28
JP2022538908A (ja) 2022-09-06
CN114222752A (zh) 2022-03-22
MX2021015974A (es) 2022-04-26
AU2020299398A1 (en) 2022-02-24
CR20220047A (es) 2022-06-23
PE20221004A1 (es) 2022-06-15
EP3994150A4 (en) 2023-08-02
BR112021025720A2 (pt) 2022-06-21
PH12021553289A1 (en) 2022-08-01
DOP2021000268A (es) 2022-08-15
ECSP22007981A (es) 2022-05-31
AR119346A1 (es) 2021-12-09

Similar Documents

Publication Publication Date Title
CN114222752B (zh) 抗组织因子抗体-药物缀合物及相关方法
CN111818943B (zh) 抗组织因子抗体、抗体-药物缀合物及相关方法
CN114174317A (zh) 鹅膏毒素抗体-药物缀合物及其用途
JP2021500375A (ja) Ｃｄ１１７＋細胞を減らすための組成物及び方法
JP2018516539A (ja) 抗ｃ−Ｍｅｔ抗体および抗ｃ−Ｍｅｔ抗体−細胞毒性薬物複合体ならびにそれらの医薬用途
JP6251682B2 (ja) メラノーマ治療の治療の組み合わせ及び方法
TW202308699A (zh) Ｃｄ７０結合劑、其結合物及其使用方法
EP3545974A1 (en) Medical use of anti-c met antibody-cytotoxic drug conjugate
TW202304524A (zh) Folr1結合劑、其結合物及使用方法
US20260034237A1 (en) Linkers, drug linkers and conjugates thereof and methods of using the same
WO2023160651A1 (zh) 一种抗体及其药物偶联物和用途
JP2023549925A (ja) 抗ｃｄ４８抗体、抗体薬物コンジュゲート及びその使用
CN119343374A (zh) 新的掩蔽抗体
EA052782B1 (ru) Конъюгаты антитело к тканевому фактору-лекарственное средство и связанные способы
JP2025517612A (ja) 抗Ｌｙ６Ｅ抗体、免疫コンジュゲートおよびその使用
WO2026069278A1 (en) Anti-cd123 antibodies and neodegrader conjugates
JP2026031518A (ja) 抗潜在型ＴＧＦ－β１抗体の使用
KR20250148670A (ko) 치료용 결합 분자를 사용한 암 치료를 위한 병용 요법
BR122025029157A2 (pt) Anticorpo que se liga ao domínio extracelular do fator tecidual humano (tf), método para sua produção, polinucleotídeo isolado ou conjunto de polinucleotídeos, vetor ou conjunto de vetores, célula hospedeira, composição e kit
BR122024018245A2 (pt) Anticorpo que se liga ao domínio extracelular do fator tecidual humano (tf), método de produção do mesmo, polinucleotídeo isolado, vetor, célula hospedeira, composição farmacêutica e kit
BR122025029156A2 (pt) Anticorpo que se liga ao domínio extracelular do fator tecidual humano (tf), método para sua produção, polinucleotídeo isolado ou conjunto de polinucleotídeos, vetor ou conjunto de vetores, célula hospedeira, composição e kit
HK1197376B (en) Therapeutic combinations and methods of treating melanoma
HK1197376A (en) Therapeutic combinations and methods of treating melanoma

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: California, USA

Applicant after: Iconock treatment Co.

Applicant after: Yeast Biopharmaceutical Co.,Ltd.

Address before: California, USA

Applicant before: Iconock treatment Co.

Applicant before: ZYMEWORKS Inc.

CB02 Change of applicant information
CB02 Change of applicant information

Address after: California, USA

Applicant after: Iconock treatment Co.

Applicant after: Enzymatic British Columbia Ltd.

Address before: California, USA

Applicant before: Iconock treatment Co.

Applicant before: Yeast Biopharmaceutical Co.,Ltd.

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20250317

Address after: California, USA

Applicant after: EXELIXIS, Inc.

Country or region after: U.S.A.

Applicant after: Enzymatic British Columbia Ltd.

Country or region after: Canada

Address before: California, USA

Applicant before: Iconock treatment Co.

Country or region before: U.S.A.

Applicant before: Enzymatic British Columbia Ltd.

Country or region before: Canada

GR01 Patent grant
GR01 Patent grant